Plus Therapeutics Deploys AI Platform for CNS Oncology Data Integration Starting 2026
Plus Therapeutics signed an agreement with Ephemeral Technologies to deploy an AI-native platform integrating its therapeutic, diagnostic and bioinformatics datasets for CNS oncology. Plus expects laboratory and clinical operating improvements starting in 2026 and plans to scale AI-driven decision support, patient stratification, precision oncology and real-world evidence workflows.
1. Partnership Details
Plus Therapeutics entered into a strategic agreement with Ephemeral Technologies to deploy an AI-native execution platform specifically for central nervous system oncology. Ephemeral, founded by former co-heads of Palantir’s U.S. healthcare business, will work alongside Plus to integrate and analyze complex datasets.
2. AI Platform Features
The platform will consolidate longitudinal therapeutic, diagnostic and bioinformatics data generated across Plus’ CNS oncology programs. It is designed to organize, derive actionable intelligence and support generative AI reasoning and agentic workflows tailored to precision neuro-oncology.
3. Expected Impact
Plus anticipates tangible improvements in laboratory and clinical operating efficiency beginning in 2026. Beyond that, the company plans to extend AI-driven decision support, translational analytics, patient stratification, precision oncology initiatives and real-world evidence programs to enhance drug development and patient outcomes.